Ankylosing Spondylitis Market Outlook Report 2024-2033 | Trends, Analysis, Insights, Overview

Global ankylosing spondylitis market size is expected to reach $7.89 Bn by 2028 at a rate of 7.7%, segmented as by treatment type, painkillers and non-steroidal anti-inflammatory drugs (nsaids), disease-modifying anti-rheumatic drugs (dmards)

Jun 20, 2024 - 13:04

Ankylosing Spondylitis Market Outlook Report 2024-2033 | Trends, Analysis, Insights, Overview

Overview and Scope

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints (the joints connecting the lower spine to the pelvis). It involves inflammation of the joints and entheses and affects joints, leading to pain, stiffness, and progressive loss of mobility in the spine.

Sizing and Forecast

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.41 billion in 2023 to $5.86 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to hla-b27 discovery, biologic treatments development, pain management approaches, patient advocacy and awareness, nsaids and disease modifying drugs.

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to personalized medicine approach, novel biologics development, early intervention and screening, lifestyle and diet management, telemedicine and remote monitoring. Major trends in the forecast period include biosimilar availability, targeted pain therapies, patient-reported outcomes (pros) emphasis, community support programs, regenerative medicine exploration.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Segmentation & Regional Insights

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users

North America was the largest region in the ankylosing spondylitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Major Driver Impacting Market Growth

The increasing geriatric population is expected to propel the growth of the ankylosing spondylitis market going forward. The geriatric population refers to an increase in the proportion of elderly people due to changes in the age structure of a population. This demographic shift has increased the number and proportion of people over the age of 60. Ankylosing spondylitis treatment and drugs help to improve mobility and manage pain in the geriatric population having ankylosing spondylitis condition. For instance, in October 2022, according to World Health Organization, a Switzerland-based international public health organization, by 2030, 1 out of 6 people in the world will be aged more than 60 years or above, and in 2020, there was a rise in 1 billion aged people reaching to 1.4 billion. Therefore, the increasing geriatric population is driving the growth of the ankylosing spondylitis market.

Key Industry Players

Major companies operating in the ankylosing spondylitis market report are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Sandoz International GmbH, Reliance Life Sciences Pvt. Ltd., Affibody Medical AB

The ankylosing spondylitis market report table of contents includes: